To identify the DEGs between different hematological malignancies, the patients were separated into three groups: case group (APL with FIP1L1::RARA), ALL group (three cases of B-ALL), and myeloid neoplasms (M) group (M7 and MDS). This evidence concerns the gene FIP1L1 and myelodysplastic syndrome.